IL2RA and type 1 diabetes mellitus: Clinically, despite concerns regarding Treg lineage instability raised previously, Phase I trials confirmed that a majority of infused CD25+CD127low Tregs expanded ex vivo from autologous polyclonal sources, maintain phenotypic fidelity in T1D patients.